TOVX Stock Overview
Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need.
Theriva Biologics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.74|
|52 Week High||US$4.39|
|52 Week Low||US$0.57|
|1 Month Change||-3.24%|
|3 Month Change||-49.98%|
|1 Year Change||-78.69%|
|3 Year Change||-81.71%|
|5 Year Change||-99.66%|
|Change since IPO||-99.88%|
Recent News & Updates
|TOVX||US Biotechs||US Market|
Return vs Industry: TOVX underperformed the US Biotechs industry which returned -16.1% over the past year.
Return vs Market: TOVX underperformed the US Market which returned -20.5% over the past year.
|TOVX Average Weekly Movement||9.6%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: TOVX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: TOVX's weekly volatility (10%) has been stable over the past year.
About the Company
Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company’s lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma.
Theriva Biologics, Inc. Fundamentals Summary
|TOVX fundamental statistics|
Is TOVX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TOVX income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.24|
|Net Profit Margin||0.00%|
How did TOVX perform over the long term?See historical performance and comparison